Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Endocyte Inc.
Headquarters: West Lafayette, IN, United States of America
Website: N/A
Year Founded: 1996
Status: Acquired
BioCentury | May 2, 2024
Deals
Novartis gains α-emitter, radioligand platform via $1B Mariana takeout
Largest upfront M&A payment for a preclinical biotech in three years
BioCentury | Mar 21, 2024
Data Byte
Radiopharmaceuticals could soon get their first blockbuster
Pluvicto’s steep launch appears on track to surpass $1B in sales this year
BioCentury | Mar 19, 2024
Deals
AZ deepens radiopharma commitment via $2B Fusion takeout
Deal brings more momentum for α-emitters, with Fusion’s lead program contrasting Novartis’ β-emitting Pluvicto
BioCentury | Oct 27, 2023
Product Development
Radiotherapy at ESMO: expanding indications around anchor targets
Novartis builds its case for Pluvicto in earlier-line mCRPC, while Rayze and Convergent test α-emitters in patients who progressed on β-emitters
BioCentury | Oct 12, 2023
Product Development
Slimmed down Novartis is now poised to grow value, says CEO Narasimhan
How Vas Narasimhan is managing change as he continues to chart a new course for the pharma
BioCentury | Oct 3, 2023
Deals
Lilly’s big step into radiopharma comes via $1.4B Point takeout
Looking beyond partnered programs, pharma acquires supply and manufacturing capabilities along with wholly-owned radioligand pipeline
BioCentury | Aug 12, 2022
Finance
Aug. 11 Quick Takes: Verona, CinCor raise cash on heels of data readouts
Plus Enhertu wins lung cancer approval and updates from GSK, Novartis, argenx and more
BioCentury | Aug 11, 2022
Finance
Aug. 10 Quick Takes: Karuna parlays data into year’s largest follow-on, at $750M
Plus Disc finds public path, Insilico refuels for growth and updates from BMS, Prellis and more
BioCentury | Mar 24, 2022
Deals
March 23 Quick Takes: FDA approves Novartis’ radiotherapy for prostate cancer
Plus Fujifilm buys a recombinant protein manufacturer, and updates from 4D pharma, Neurana and more
BioCentury | Jun 4, 2021
Deals
Acquisition of Babich-founded Noria helps Bayer pad radiopharmaceutical pipeline
A deal unveiled Thursday will help Bayer expand its footprint in alpha-emitting targeted radiopharmaceuticals. Bayer AG (Xetra:BAYN) announced it will acquire Noria Therapeutics Inc. and its
Items per page:
1 - 10 of 171